NEW YORK (GenomeWeb News) – GE Global Research and Singapore's Agency of Science, Technology, and Research said on Thursday that they have signed a memorandum of understanding to combine their capabilities for the faster, earlier, and more accurate diagnosis of cancer and other diseases.
As part of the collaboration, GE will integrate its molecular diagnostics technology with A*STAR's Singapore Bioimaging Consortium's biomedical imaging and preclinical model development expertise to develop novel imaging markers for hepatic cellular carcinoma, the most common form of liver cancer in Asia. The goal is to develop new platforms that can be used to characterize HCC in each patient so that a therapy can be tailored specifically for that patient.
A*STAR and GE Global Research, the central technology development arm of GE Healthcare and all of GE's businesses, will also work to improve medical imaging technologies in imaging modalities, such as magnetic resonance imaging, positron emission tomography, and computed tomography.
Financial terms of the deal were not disclosed.
The agreement builds on an earlier deal between GE and A*STAR's Singapore Bioimaging Consortium using hyperpolarized carbon-13 technology to investigate sub-second biochemical imaging for cancer applications. Results from that partnership "helped pave the way for a broader scientific collaboration on projects in medical diagnostics and medical imaging," ASTAR and GE said in a joint statement.